Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
Cash from Investing Activities
Denali Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Cash from Investing Activities
-$188m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$20.8B
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-37%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$3.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.8B
|
CAGR 3-Years
-123%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-19%
|
|
Denali Therapeutics Inc
Glance View
In the heart of the biotech innovation hub that is California, Denali Therapeutics Inc. emerges as a promising beacon in the landscape of neurodegenerative disease treatment. Established by a team of pioneers in 2015, the company aims to combat the pressing challenge of diseases like Alzheimer's, Parkinson’s, and ALS. At the core of Denali’s mission is a sophisticated approach that intersects genetics, engineering, and clinical research. This biotech firm is not just about dreaming big; it operationalizes its vision through a science-driven methodology. Denali leverages its proprietary "Transport Vehicle" technology to enhance the delivery of therapeutic antibodies across the blood-brain barrier—a critical hurdle in treating neurological disorders. By addressing genetic underpinnings and homeostasis dysfunctions, Denali positions itself as a driver of transformative healthcare solutions. Denali's business model revolves around the development and commercialization of novel therapeutics. With a focus on high unmet needs, the company aligns its research objectives with revenue generation through strategic collaborations and partnerships. These alliances bolster Denali’s financial foundation, offering resources and expertise to hasten drug development and commercialization. Denali engages in research and licensing agreements that bring in upfront payments, milestone rewards, and future royalties. This approach not only diversifies its income streams but also mitigates risks associated with drug development intricacies. As Denali nurtures its pipeline, revenue opportunities expand, resting on the successful translation of groundbreaking science into tangible, market-ready solutions that offer hope to millions grappling with debilitating neurological conditions.
See Also
What is Denali Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
-188m
USD
Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's Cash from Investing Activities amounts to -188m USD.
What is Denali Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
19%
The average annual Cash from Investing Activities growth rates for Denali Therapeutics Inc have been 19% over the past three years .
You don't have any saved screeners yet